Elligo Health Research, a healthcare-enabling research organization, has received a grant from the U.S. Food and Drug Administration (FDA) for a follow-on project to extend the value of common data harmonization in the generation of clinical evidence from real-world data (RWD) to support regulatory use.
This grant will enable Elligo to explore methodology and use cases to further goals of the 21st Century Cures Act related to facilitating data sharing. Achievements from the first phase of this project include mappings of multiple data models (OMOP, PCORnet, i2b2, and Sentinel) to the BRIDG Model (an HL7, CDISC, and ISO standard), a reference data model and terminology bindings. These products, which have been catalogued by the National Cancer Institute, will be leveraged in the new project, along with HL7’s FHIR standard.
“This project has been challenging, but educational and rewarding for us as an institution participating in multiple research networks that currently request de-identified data in as many different formats,” said Samuel Volchenboum, MD, PhD, associate chief research informatics officer of the University of Chicago’s Center for Research Informatics. “We look forward to benefiting from the harmonization products in our future clinical research activities.”
“Elligo is pleased to have the opportunity to continue our work with FDA, NCATS, NCI, and data partners to apply learnings from the first phase of this project,” said Rebecca Kush, PhD, Elligo chief scientific officer. “An efficient learning health system to benefit patients will depend on broad adoption of harmonized data models and terminologies, while concurrently protecting data and reducing legal barriers to sharing research data.”
“Elligo is proud to support the FDA in this important project,” said John Potthoff, PhD, Elligo CEO. “Elligo’s mission, to enable community physicians and their patients to participate in research, will be facilitated through this work.”
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.